Genotyping and Genomic Sequencing in Clinical Practice

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 761-795

  Gish, Robert G ^a   Locarnini, Stephen ^b,c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CLEVUDINE; DEOXYGUANOSINE DERIVATIVE; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; MUTANT PROTEIN; NUCLEIC ACID; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; THREONINE; VIRUS DNA;

ANTIBIOTIC RESISTANCE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; PATIENT MONITORING; PREVALENCE; PUBLIC HEALTH PROBLEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS CARRIER; VIRUS GENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; SEQUENCE ANALYSIS, DNA;

EID: 35548990478     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.008     Document Type: Review

References (148)

1. Hoofnagle J.H. Chronic hepatitis B. N Engl J Med 323 (1990) 337-339
2. Maynard J.E. Hepatitis B: global importance and need for control. Vaccine 8 Suppl (1990) S18-S20
3. Dodd R.Y., and Nath N. Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States. J Virol Methods 17 (1987) 81-94
4. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
5. Chu C.M. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 15 Suppl (2000) E25-E30
6. de Jongh F.E., Janssen H.L., De Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen- positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
7. de Franchis R., Meucci G., Vecchi M., et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 118 (1993) 191-194
8. Fattovich G., Brollo L., Giustina G., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 32 (1991) 294-298
9. Lok A.S. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 10 (1992) 46-52
10. McQuillan G.M., Coleman P.J., Kruszon-Moran D., et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. [see comments]. Am J Public Health 89 (1999) 14-18
11. Gish R.G., and Gadano A.C. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 13 (2006) 787-798
12. Lee T.A., Veenstra D.L., Iloeje U.H., et al. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 38 (2004) S144-S147
13. Gish R.G., and Locarnini S.A. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 4 (2006) 666-676
14. Lin H.H., Wu W.Y., Kao J.H., et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. J Gastroenterol Hepatol 21 (2006) 605-609
15. Bortolotti F., Bertaggia A., Crivellaro C., et al. Chronic evolution of acute hepatitis type B: prevalence and predictive markers. Infection 14 (1986) 64-67
16. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
17. Ikeda K., Arase Y., Kobayashi M., et al. Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology 48 (2005) 29-38
18. Yu M.W., Yeh S.H., Chen P.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
19. Yuen M.F., Yuan H.J., Wong D.K., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
20. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
21. Keeffe E.B., and Marcellin P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 285-294
22. Kaneko S., Kobayashi K., and Miller R.H. Detection of hepatitis B virus DNA using the polymerase chain reaction technique. J Clin Lab Anal 4 (1990) 479-482
23. Bonino F., Hoyer B., Nelson J., et al. Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. Hepatology 1 (1981) 386-391
24. Bartholomeusz A., and Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol 14 (2004) 3-16
25. Wiegand J., Hasenclever D., and Tillman H.L. Should treatment of hepatitis B depend on HBV genotypes? - a hypothesis generated from an explorative analysis of published evidence. Hepatology 44 Suppl 1 (2006) 564A-565A
26. Flink H.J., van Zonneveld M., Hansen B.E., et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 (2006) 297-303
27. Chien R.N., Lin C.Y., Yeh C.T., et al. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. J Viral Hepat 13 (2006) 845-850
28. Chien R.N., Yeh C.T., Tsai S.L., et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 (2003) 1267-1273
29. Kobayashi M., Suzuki F., Akuta N., et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 78 (2006) 1276-1283
30. Schildgen O., Sirma H., Funk A., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
31. Osiowy C., Villeneuve J.P., Heathcote E.J., et al. Detection of rtN236T and rtA181 V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 44 (2006) 1994-1997
32. Bonino F., Marcellin P., Lau G.K., et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (2007) 699-705
33. Chan H.L., Hui A.Y., Wong M.L., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53 (2004) 1494-1498
34. Kobayashi M., Akuta N., Suzuki F., et al. Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. J Med Virol 78 (2006) 60-67
35. Ganne-Carrie N., Williams V., Kaddouri H., et al. Significance of hepatitis B virus genotypes A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis District of Paris. J Med Virol 78 (2006) 335-340
36. Guarnieri M., Kim K.H., Bang G., et al. Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol 80 (2006) 587-595
37. Livingston S.E., Simonetti J.P., McMahon B.J., et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 195 (2007) 5-11
38. Yuen M.F., Tanaka Y., Mizokami M., et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 25 (2004) 1593-1598
39. Lim C.K., Tan J.T., Khoo J.B., et al. Correlations of HBV genotypes, mutations affecting HBeAg expression and HBeAg/anti-HBe status in HBV carriers. Int J Med Sci 3 (2006) 14-20
40. Sheu M.J., Lin C.Y., Sun C.S., et al. Nonresponse to 18-month lamivudine monotherapy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation. J Formos Med Assoc 105 (2006) 588-593
41. Liaw Y.F., and Sollano J.D. Factors influencing liver disease progression in chronic hepatitis B. Liver Int 26 Suppl 2 (2006) 23-29
42. Chu C.J., Keeffe E.B., Han S.H., et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 125 (2003) 444-451
43. Lau G.K., Piratvisuth T., Luo K.X., et al. Durability of response and occurrence of late response to peginterferon alfa-2a (40KD) (Pegasys) one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 44 Suppl 2 (2006) S23-S24
44. Chen C.H., Lee C.M., Lu S.N., et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 44 (2006) 76-82
45. Simmonds P., and Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes. J Virol 79 (2005) 15467-15476
46. Tanaka Y., Mukaide M., Orito E., et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 45 (2006) 646-653
47. Tiollais P., Pourcel C., and Dejean A. The hepatitis B virus. Nature 317 (1985) 489-495
48. Angus P.W. Review: hepatitis B and liver transplantation. J Gastroenterol Hepatol 12 (1997) 217-223
49. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4 Suppl 1 (1997) 11-20
50. Coleman P.F. Detecting hepatitis B surface antigen mutants. Emerging Infect Dis 12 (2006) 198-203
51. Carman W.F., Zanetti A.R., Karayiannis P., et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336 (1990) 325-329
52. Hsu H.Y., Chang M.H., Ni Y.H., et al. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 26 (1997) 786-791
53. Mast E.E., Mahoney F.J., Alter M.J., et al. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine 16 Suppl (1998) S48-S51
54. Jilg W. Hepatitis B-Bedeutung für die transfusionsmedizin. Infusionsther Transfusionsmed 21 Suppl 1 (1994) 20-26
55. Weber B., Bayer A., Kirch P., et al. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol 37 (1999) 2639-2647
56. Raimondo G., Pollicino T., Cacciola I., et al. Occult hepatitis B virus infection. J Hepatol 46 (2007) 160-170
57. Shaw T., and Locarnini S.A. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 6 (1999) 89-106
58. Doutreloigne J., Libbrecht E., Van Assche E., et al. A line probe assay (LiPA) for detecting novel hepatitis B drug resistance mutations associated with entecavir, tenofovir and adefovir dipivoxil therapy. Hepatology 44 Suppl 1 (2006) 552A-554A
59. Olivero A., Ciancio A., Abate M.L., et al. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. J Viral Hepat 13 (2006) 355-362
60. Paik Y.H., Han K.H., Hong S.P., et al. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 11 (2006) 447-455
61. Lee C.H., Kim S.O., Byun K.S., et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 130 (2006) 1144-1152
62. Cai F., Chen H., Hicks C.B., et al. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods 4 (2007) 123-125
63. Dusheiko G. Lamivudine therapy for hepatitis B infection. Scand J Gastroenterol 230 Suppl (1999) 76-81
64. Dienstag J.L. Sexual and perinatal transmission of hepatitis C. Hepatology 26 (1997) 66S-70S
65. Dienstag J.L., Schiff E.R., Mitchell M., et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 30 (1999) 1082-1087
66. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 (2000) 172-180
67. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
68. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
69. Dienstag J.L., Perrillo R.P., Schiff E.R., et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333 (1995) 1657-1661
70. Lai C.L., Ching C.K., Tung A.K., et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25 (1997) 241-244
71. Nevens F., Main J., Honkoop P., et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113 (1997) 1258-1263
72. Honkoop P., De Man R.A., Niesters H.G., et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepat 5 (1998) 307-312
73. Bartholomew M.M., Jansen R.W., Jeffers L.J., et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349 (1997) 20-22
74. Ling R., Mutimer D., Ahmed M., et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24 (1996) 711-713
75. Tipples G.A., Ma M.M., Fischer K.P., et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24 (1996) 714-717
76. Honkoop P., Niesters H.G., De Man R.A., et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 26 (1997) 1393-1395
77. Chayama K., Suzuki Y., Kobayashi M., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711-1716
78. Liaw Y.F., Chien R.N., Yeh C.T., et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
79. Seta T., Yokosuka O., Imazeki F., et al. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 60 (2000) 8-16
80. Benhamou Y., Bochet M., Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30 (1999) 1302-1306
81. Bessesen M., Ives D., Condreay L., et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28 (1999) 1032-1035
82. Thibault V., Benhamou Y., Seguret C., et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 37 (1999) 3013-3016
83. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
84. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
85. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29 (1999) 889-896
86. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
87. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 (2004) 1276-1282
88. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
89. Ogata N., Fujii K., Takigawa S., et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59 (1999) 270-276
90. Delaney W.E., Yang H., Westland C.E., et al. The hepatitis B virus polymerase mutation rtV173 L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77 (2003) 11833-11841
91. Bartholomeusz A., Schinazi R., and Locarnini S. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepat Rev 4 (1998) 167-187
92. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
93. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
94. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
95. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
96. Marcellin P., Chang T.T., and Lim S.G. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology 44 Suppl 1 (2006) 548A
97. Chang T.T., Shiffman M., Tong M., et al. Durability of HBeAg seroconversion after adefovir dipivoxil (ADV) treatment for chronic hepatitis B (CHB). J Hepatol 40 Suppl 1 (2004) 126
98. Hadziyannis S.J., Sevastianos V., Rapti I., et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. [abstract]. Hepatology 44 Suppl 1 (2006) 231A-232A
99. Hepsera (adefovir dipivoxil). [package insert] (2006), Gilead Sciences, Redwood City (CA)
100. Bartholomeusz A., Tehan B.G., and Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 9 (2004) 149-160
101. Yeon J.E., Yoo W., Hong S.P., et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55 (2006) 1488-1495
102. Lampertico P., Marzano A., and Levrero M. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 44 Suppl 1 (2006) 693A-694A
103. Sung JJY, Lai JY, Zeuzem S, et al. A randomised, double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. Presented at the 38th Annual Meeting of the European Association for the Study of the Liver. Geneva, Switzerland, July 3-6, 2003.
104. Lampertico P., Viganò M., Manenti E., et al. No evidence for adefovir resistance in HBeAg-negative lamivudine resistant patients treated with lamivudine-adefovir combination for 3 years. J Hepatol 44 Suppl 2 (2006) S186
105. Lee Y.S., Suh D.J., Lim Y.S., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
106. Lok A.S., Fung S.K., and Han S.H. Virological response and resistance to adefovir therapy in liver transplant patients. Hepatology 42 Suppl 1 (2006) 232A
107. Zhang W.X., Lai V., Mutimer D., et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatobiliary Pancreat Dis Int 5 (2006) 154-156
108. Sheldon J., Camino N., Rodes B., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 (2005) 727-734
109. Colonno R.J., Genovesi E.V., Medina I., et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184 (2001) 1236-1245
110. De Man R.A., Wolters L.M., Nevens F., et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34 (2001) 578-582
111. Innaimo S.F., Seifer M., Bisacchi G.S., et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 41 (1997) 1444-1448
112. Lai C.L., Rosmawati M., Lao J., et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 (2002) 1831-1838
113. Seifer M., Hamatake R.K., Colonno R.J., et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 42 (1998) 3200-3208
114. Wolters L.M., Hansen B.E., Niesters H.G., et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 37 (2002) 137-144
115. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
116. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
117. Baraclude (entecavir). [package insert] (2007), Bristol-Myers Squibb Company, Princeton (NJ)
118. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
119. FDA Antiviral Drugs Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4094T1.htm. Accessed September 9, 2007.
120. Gish R.G., Chang T.T., De Man R.A., et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology 42 Suppl 1 (2005) 267A-268A
121. Chang T.T., Chao Y.C., and Kaymakoglu S. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naïve HBeAg(+) patients (ETV 022/901). Hepatology 44 Suppl 1 (2006) 229A
122. Shouval D., Akarca U.S., Hatzis G., et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). J Hepatol 44 Suppl 2 (2006) S21-S22
123. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
124. Colonno R.J., Rose R.E., Pokornowski K., et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside-naive patients while resistance emergence increases over time in lamivudine-refractory patients. [abstract]. Hepatology 44 Suppl 1 (2006) 229A-230A
125. Colonno R.J., Ros R.E., Pokornowski K., et al. Four year assessment of entecavir resistance in nucleoside-naive and lamivudine-refractory patients. J Hepatol 46 Suppl 1 (2007) S294
126. Colonno R.J., Rose R.E., Levine S.M., et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology 40 Suppl 1 (2004) 661A
127. Tenney D.J., Langley D.R., Oliver A.J., et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 40 Suppl 1 (2004) 245A
128. Warner N., Locarnini S.A., Edwards R., et al. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy. Hepatology 40 Suppl 1 (2004) 245A
129. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
130. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
131. Lai C.L., Gane E., and Hsu C.W. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology 44 Suppl 1 (2006) 222A
132. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
133. Kim J.W., Park S.H., and Louie S.G. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother 40 (2006) 472-478
134. Han S.H. Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 14 (2005) 511-519
135. Lai C.L., Leung N., Teo E.K., et al. Results of a one-year international phase IIb comparative trial of LdT, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology 38 Suppl 1 (2003) 262A
136. Chin R., Shaw T., Torresi J., et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-B-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-B-L-arabinofuranosyluracil. Antimicrob Agents Chemother 45 (2001) 2495-2501
137. Delaney IV W.E., Locarnini S., and Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 12 (2001) 1-35
138. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
139. Ono-Nita S.K., Kato N., Shiratori Y., et al. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother 46 (2002) 2602-2605
140. Levine S., Hernandez D., Yamanaka G., et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46 (2002) 2525-2532
141. Angus P., and Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!. Antivir Ther 9 (2004) 145-148
142. Xiong X., Flores C., Yang H., et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28 (1998) 1669-1673
143. Xiong X., Yang H., Westland C.E., et al. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 31 (2000) 219-224
144. Perrillo R., Schiff E., Yoshida E., et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32 (2000) 129-134
145. Peters M.G., Singer G., Howard T., et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 68 (1999) 1912-1914
146. Samuel D., Zignego A.L., Reynes M., et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 21 (1995) 333-339
147. Perrillo R., Rakela J., Dienstag J., et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 29 (1999) 1581-1586
148. Terrault N.A., Holland C.C., Ferrell L., et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 2 (1996) 132-138